Kyu Kwang Kim

Summary

Affiliation: Women and Infants' Hospital
Country: USA

Publications

  1. pmc Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI 02905, USA
    BMC Cancer 12:147. 2012
  2. pmc Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
    Ashley Stuckey
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants7 Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 11:308. 2011
  3. pmc Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 6:e19049. 2011
  4. doi Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI, USA
    Gynecol Oncol 122:183-9. 2011
  5. doi Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Providence, RI 02905, USA
    Int J Oncol 40:227-35. 2012
  6. pmc Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 3:e2303. 2008
  7. pmc Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 10:72. 2010
  8. pmc Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Warren Alpert Medical School of Brown University, Providence, RI 02905, USA
    Invest New Drugs 28:543-53. 2010
  9. pmc A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells
    Rakesh K Singh
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gysnecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 109:240-9. 2008
  10. ncbi Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro
    Rakesh K Singh
    Women and Infants Hospital, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, RI, USA
    Cancer Biol Ther 11:1036-45. 2011

Collaborators

Detail Information

Publications17

  1. pmc Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI 02905, USA
    BMC Cancer 12:147. 2012
    ....
  2. pmc Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
    Ashley Stuckey
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants7 Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 11:308. 2011
    ..In this study we identify genes and gene networks important for the efficacy of a pre-clinical anti-tumor therapeutic, MT19c...
  3. pmc Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 6:e19049. 2011
    ..We report here that Fe-SP is a potent growth-suppressing and cytotoxic agent for in vitro NB cell lines and, due to its high tolerance in previous animal toxicity studies, a potential therapeutic drug to treat NB tumors in vivo...
  4. doi Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI, USA
    Gynecol Oncol 122:183-9. 2011
    ..This study tests the hypothesis that TM can modulate antioxidants in tumor cells and render doxorubicin resistant tumor cells sensitive to doxorubicin...
  5. doi Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Providence, RI 02905, USA
    Int J Oncol 40:227-35. 2012
    ....
  6. pmc Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 3:e2303. 2008
    ....
  7. pmc Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 10:72. 2010
    ..In present study, we evaluated the effects of various lipophilic aroylhydrazone chelators (AHC), including novel compound HNTMB, on various ovarian cancer cell lines (SKOV-3, OVCAR-3, NUTU-19)...
  8. pmc Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Warren Alpert Medical School of Brown University, Providence, RI 02905, USA
    Invest New Drugs 28:543-53. 2010
    ..B3CD possesses anti-ovarian cancer properties in vitro and in vivo. We propose the further development of non-calcemic bromoacetoxy derivatives of vitamin D(3) as potential anti-cancer therapeutics...
  9. pmc A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells
    Rakesh K Singh
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gysnecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 109:240-9. 2008
    ..Key mechanisms of the cellular response in vitro were studied and suggest a potential of 7Me-IEITC as a therapeutic drug...
  10. ncbi Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro
    Rakesh K Singh
    Women and Infants Hospital, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, RI, USA
    Cancer Biol Ther 11:1036-45. 2011
    ....
  11. doi Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines
    Timothy C Horan
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, 101 Dudley Street, Providence, RI 02905, USA
    Invest New Drugs 30:1460-70. 2012
    ..Key mechanisms during cell death are predominantly correlated to excess generation of ROS. We suggest the further development of ABITC as a potential therapeutic by studying the drug efficacy in EC in-vivo models...
  12. pmc A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells
    Rakesh K Singh
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, The Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI 02905, USA
    Invest New Drugs 29:63-72. 2011
    ....
  13. doi Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines
    Laurent Brard
    Department of Obstetrics and Gynecology, Alpert Medical School, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 123:370-8. 2011
    ..This study was designed to evaluate a novel non-hypercalcemic vitamin-D derivative (MT19c) and its anticancer effects in cultured ovarian cancer cell model...
  14. pmc Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Providence, RI 02905, USA
    Chem Biol Drug Des 70:302-10. 2007
    ..These results suggest that B3CD could be developed as a treatment for NB...
  15. pmc Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model
    Thilo S Lange
    Division of Biology and Medicine, Brown University, Providence, RI, USA
    Drug Des Devel Ther 3:17-26. 2009
    ..An ovarian cancer animal model showed that the chemotherapeutic relevant dose of Fe-SP in rats is 0.5-1 mg/kg body weight. The present report suggests that Fe-SP is a potential therapeutic drug to treat ovarian cancer...
  16. pmc Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Departments of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI, USA
    Sci Rep 5:15911. 2015
    ..We furthermore provide evidence that TM may provide an additional benefit by potentiating p38 activation following cisplatin treatment, which may in turn promote receptor degradation by cisplatin. ..
  17. pmc Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Departments of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI, USA
    Sci Rep 5:14296. 2015
    ..Our studies provide mechanistic evidence for TM-mediated HIF-1α regulation and suggest its therapeutic potential as a method of blocking angiogenesis in ovarian and endometrial tumors. ..